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Background: p53 is a tumour suppressor protein that plays a key role in many steps of apoptosis, and malfunctioning
of this transcription factor leads to tumorigenesis. Prognosis of many tumours also depends upon the p53 status. Most
of the clinically used anticancer compounds activate p53 dependent pathway of apoptosis and hence require p53 for
their mechanism of action. Further, Ras/Raf/MEK/ERK axis is an important signaling pathway activated in many cancers.
Dependence of diaminothiazoles, compounds that have gained importance recently due to their anticancer and anti
angiogenic activities, were tested in cancer models with varying p53 or Ras/Raf mutational status.
Methods: In this study we have used p53 mutated and knock out colon cancer cells and xenograft tumours to study
the role of p53 in apoptosis mediated by diaminothiazoles. Colon cancer cell lines with varying mutational status for
Ras or Raf were also used. We have also examined the toxicity and in vivo efficacy of a lead diaminothiazole 4-
Amino-5-benzoyl-2-(4-methoxy phenylamino)thiazole (DAT1) in colon cancer xenografts.
Results: We have found that DAT1 is active in both in vitro and in vivo models with nonfunctional p53. Earlier
studies have shown that extrinsic pathway plays major role in DAT1 mediated apoptosis. In this study, we have
found that DAT1 is causing p53 independent upregulation of the death receptor 5 by activating the Ras/Raf/
MEK/ERK signaling pathway both in wild type and p53 suppressed colon cancer cells. These findings are also
confirmed by the in vivo results. Further, DAT1 is more efficient to induce apoptosis in colon cancer cells with
mutated Ras or Raf.
Conclusions: Minimal toxicity in both acute and subacute studies along with the in vitro and in vivo efficacy of
DAT1 in cancers with both wild type and nonfunctional p53 place it as a highly beneficial candidate for cancer
chemotherapy. Besides, efficiency in cancer cells with mutations in the Ras oncoprotein or its downstream kinase
Raf raise interest in diaminothiazole class of compounds for further follow-up.
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p53 is a tumour suppressor protein that plays a key role
in the cellular response to stress and hence acts as a
major obstructer of tumorigenesis. Once stimulated by
numerous external and internal stress signals, p53 accu-
mulates in the nucleus in its active form leading to
either growth arrest or apoptosis. It also contributes to
cellular processes such as cellular differentiation, DNA
repair and angiogenesis. More than 50 % of human
cancers have mutation in the p53 gene which renders it
non functional. In many other cancer cases, a loss of
p53 function happens through indirect inactivation of
the protein when some viral proteins bind to it or due to
the mutation of the genes that produce proteins interact-
ing with p53 [1].
In vitro and in vivo studies have implicated the import-
ance of p53 in apoptosis induced by chemotherapy [2].
Many of the currently used anticancer compounds have
a p53 dependent mode of action and most of the cases,
p53 acts as a proapoptotic protein. It can be supposed
that loss of p53 function can confer resistance to chemo-
therapy. Indeed, reduced efficacy has been reported for
some chemotherapies in tumours with suppressed or
mutated p53 [3, 4].
p53 can mediate both extrinsic and intrinsic pathways
of apoptosis. Extrinsic pathways of apoptosis is mediated
by death receptors belonging to Tumour Necrosis Factor
(TNF) super family, finally leading to activation of caspase
8 [5]. On the other hand, mitochondria along with the
BCl2 family of proteins play a major role in intrinsic path-
way of apoptosis leading to the activation of caspase 9 [6,
7]. The extrinsic pathway can be mediated by p53 through
the induction of genes encoding three transmembrane
proteins Fas, DR5 and PERP [8–10]. p53 also plays a
major role in the intrinsic pathway of apoptosis by the in-
duction of Bax [11], Puma [12], Noxa [13] and APAF-1
[14–16] which facilitate the release of cytochrome c from
the mitochondria.
However a large body of evidence suggests that p53
independent apoptotic pathways also occur. It has been
shown that in p53 deficient cells, Chk1, Chk2 and ABL
upregulates p73 which restores the transactivation of
p53 target genes [17, 18]. MAPKs and transciption
factors like E2F1, FOXO1 brings about p53 independent
activation of caspase 3 in a mitochondria dependent or
independent manner [19–21]. p53 independent coupling
of DNA damage to caspase 3 activation can also happen
via cytosolic translocation of Nur22 which is a nuclear
protein [22].
p53 activity is mainly modulated by phosphorylation at
different sites and several upstream kinases play major roles
in this process. Ras/MAPK pathway has been shown to
have role in p53 phosphorylation and modulation in both
in vitro and in vivo models [23]. Cyclin A/B-cdc2complexes also take part in p53 phosphorylation and
hence may also be involved in its stabilization [24].
Diaminothiazoles are a group of antimitotic compounds
that inhibit different cancer cell lines by binding to the
colchicine binding site of tubulin reversibly [25–27]. They
are also effective in multidrug resistant cancers [28]. They
are shown to inhibit angiogenesis efficiently [29]. The lead
diaminothiazole DAT1 potentiates independent extrinsic
pathway activation of apoptosis through upregulation of
the death receptor DR5 [30]. DR5 is a member of the TNFR
family which contains an extra cellular domain and a
domain, which can bind to adaptor moleceules that contain
a death domain. This domain then interacts with the initi-
ator caspase 8 to bring about apoptosis. DR5 can initiate
apoptosis in a ligand independent manner also [31–33].
Initially DR5 has been shown as a downstream target of
p53 [10]. But recently many groups have shown that DR5
can be upregulated independently of p53 [34–37]. In this
study, we have investigated the signaling pathways eluci-
dated by a lead diaminothiazole DAT1 in vitro and in vivo.
The toxicity studies have been undertaken. The role of p53
in DAT1 mediated signaling events and apoptosis were
studied. We have also investigated the efficiency of DAT1
in cell lines with varying Ras/Raf mutational status.
Results
Efficacy of DAT1 in cell lines with nonfunctional p53
Many of the anticancer compounds need p53 for their
mechanism of action. However, from the light of numerous
studies conducted recently, it can be concluded that correl-
ation of drug sensitivity with p53 status depends very much
on the drug and cell type. To test the activity of DAT1 in
cell lines where the action of p53 is suppressed, we have
used colon cancer cell lines HT29, SW620 and SW480 with
mutated p53 [38] and HCT116 p53−/−, an isogenic p53
knock out (p53 −/−) line and compared with p53 wild type
cell line HCT116 (p53 +/+). The half inhibitory concentra-
tion (IC50) of DAT1 was determined in these cell lines by
MTTassay and was compared with the widely used chemo-
therapeutic agents paclitaxel (taxol®), vinblastine and 5-
fluorouracil. DAT1 was effective in all these cell lines in a
comparable manner irrespective of their p53 status
(Table 1). As reported earlier [39–42], taxol maintained its
efficacy in cell lines with nonfunctional p53, whereas
vinblastine and 5-fluorouracil had decreased efficiency
in most of these cell lines.
DAT1 was earlier shown to induce apoptosis in different
cell lines [30]. Treatment of DAT1 to the cell lines with
nonfunctional p53 followed by staining with the DNA
binding dye DAPI detected condensation of chromosomes
(Fig. 1a) which is a hallmark of apoptosis. Quantitation of
apoptosis showed that DAT1 was quite effective in all
these cell lines (Fig. 1b). The effector caspase 3 activation
was also observed in these cell lines (Fig. 1c). However,
Table 1 Comparison of IC50 values of DAT1 with other antimitotic drugs. Cells were treated with the drugs and MTT assay was
performed as given in the methods section. Half inhibitory concentration was obtained using the programme Origin
Cell line DAT1 (μM) Vinblastine (μM) Taxol (μM) 5 fluoro uracil (μM)
HCT116 0.3 ± 0.08 0.004 ± 0.002 0.014 ± 0.007 8.69 ± 0.54
HCT116 p53 -/- 0.7091 ± 0.08 0.0195 ± 0.0007 0.006 ± 0.002 19.34 ± 1.34
SW 620 0.42 ± 0.07 0.3 ± 0.09 0.0245 ± 0.006 9.65 ± 0.33
SW 480 0.795 ± 0.09 3.385 ± 0.247 0.0315 ± 0.0014 18.65 ± 0.68
HT 29 0.2 ± 0.08 0.0015 ± 0.0007 0.01 ± 0.0014 20.18 ± 0.77
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failed to induce apoptosis in p53 knock out (p53 −/−) line
at a concentration of 0.01 μM, a concentration in which it
displayed large apoptotic response in the p53 wild type
HCT116 cells (Additional file 1: Figure S1).
A number of earlier studies indicate that p53 is crucial
in the mitochondria mediated apoptotic pathway. How-
ever, the extrinsic pathway can be both p53 dependent
or independent. Previous studies from our laboratory
showed the involvement of both apoptotic pathways in
DAT1 mediated apoptosis with major contribution from
an independent extrinsic pathway. Since DAT1 was also
found to be highly efficient in cells where the intrinsic
pathway was blocked [30], it seemed worthwhile to
analyze whether the extrinsic pathway of apoptosis caused
by DAT1 would be p53 mediated.
Western blotting of lysates prepared from cells treated
with DAT1 for different time periods showed that DAT1
caused caspase 8 activation in cell lines irrespective of
their p53 status (Fig. 1c).
p53 independent activation of DR5 by DAT1
Several downstream targets of p53 are involved in apop-
tosis. Bax, PIGs (p53 induced genes), Fas/APO-1, DR5 are
some of the downstream targets of apoptosis that play
major roles in apoptosis [34]. Previous studies from our
laboratory have shown that DAT1 mediated apoptosis de-
pends mainly on the DR5 activation [30]. DR5 is a mem-
ber of the TNFR family and is homologous to the other
death receptor DR4 [43]. Both DR4 and DR5 gets acti-
vated when bound by its substrate TRAIL and recruits Fas
associated death domain (FADD) which in turn recruits
caspase 8 and initiates extrinsic pathway of apoptosis.
DAT1 treatment caused DR5 upregulation in cells with
non functional p53 confirming that DAT1 mediated DR5
induction is p53 independent (Fig. 2a). There was no con-
siderable change in the levels of DR4 and the other mem-
ber of the TNF receptor family, Fas receptor, after DAT1
treatment (Fig. 2b).
ERK activation and nuclear translocation
Mitogen activated protein kinases are serine/threonine
specific protein kinases and comprises of Extracellular
signal Regulated stress Kinases (ERK), c-Jun N-terminalkinase/stress activated protein kinases (JNK) and p38
kinases [44, 45]. Among the many isoforms, ERK1/2 is
the most extensively studied isoform and is activated by
phosphorylation in response to various stress stimuli
through diverse mechanisms involving the Ras-Raf-MEK
pathway. A variety of biological responses (apoptosis,
proliferation, migration and differentiation) are associ-
ated with ERK activation depending on the cell type,
duration of activation and stimulus [46, 47]. Thus we
were interested to know whether MAPK signaling has
any role in the DAT1 mediated apoptosis. Both HCT116
and HCT116 p53−/−cells were treated with DAT1 for
the indicated time periods, and P-ERK, P-p38, P-JNK
levels were checked. DAT1 caused P-ERK activation in
HCT116 and HCT116 p53−/− cells, while P-p38 and
P-JNK levels remained same (Fig. 3a). Further, im-
munofluorescence and western blotting experiments
also revealed increase in nuclear localization of P-ERK
following DAT1 treatment (Fig. 3b, c) indicating an in-
crease in their role for transcription of molecules in-
volved in further cellular processes.Decrease in apoptosis upon blocking ERK activation
U0126 is a selective inhibitor of MEK1/2 and hence pre-
vents ERK1/2 activation by its phosphorylation. HCT116
and HCT116 p53−/−cells were treated with U0126
followed by DAT1 treatment and the chromatin conden-
sation was checked by DAPI staining. It was seen that
the percentage of apoptotic cells decreased from 67 to
3 % and 60 to 5 % in HCT116 and HCT116 p53 −/− re-
spectively in the inhibitor treated cells, as compared to
cells treated with DAT1 alone (Fig. 4a). The reduction of
apoptosis was also observed by spectrofluorometric
measurement of active caspase 3 in cells treated with
DAT1 either in the presence or absence of the ERK in-
hibitor U0126. The relative fluorescence intensity (which
indicates caspase 3 activation) decreased in the presence
of U0126 as compared to treatment with DAT1 alone
(Fig. 4b). The findings were also supported using RNAi
inhibition of ERK1/2. Prominent reduction of apoptosis
as measured by chromatin condensation was observed
using siRNA against ERK1/2 as compared to scrambled
siRNA (Fig. 4c).
Fig. 1 Apoptosis induction by DAT1 in p53 mutated cell lines a. Indicated cell lines were treated with DAT1 for a period of 24 h and stained with DAPI. b.
Apoptosis was quantitated by counting the number of cells with condensed chromosomes and percentage was calculated as compared to the total number
of cells. Cells were counted from five different fields. Values expressed in the graph are the average values from three independent experiments c. Cells were
treated with DAT1 for the indicated time periods and caspase 8 and 3 activation were checked using western blotting. Band intensities determined by Biorad
Quantity one software were normalized with the levels of beta actin and fold increase was quantified with respect to the untreated ones
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Fig. 2 DR5 induction by DAT1 in p53 mutated cell lines a. HCT116 p53 −/−, SW620, SW480 and HT29 were treated with DAT1 at ~1.5 X IC50
concentration for the indicated time periods and DR5 activation was checked by western blotting. b. HCT116 p53 −/− was treated with DAT1
and western blotting was performed using DR4 and Fas antibodies
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There are many studies which show that ERK signaling
can be an upstream regulator of DR5 activation [48–50].
To check whether there is any link between ERK activa-
tion and DR5 upregulation in DAT1 mediated apoptosis,
we tested for DR5 induction following DAT1 treatment
either in the presence or absence of U0126 in HCT116
and HCT116 p53−/− cells. DR5 induction by DAT1 was
significantly hampered in presence of U0126 (Fig. 4d)
proving that DAT1 induces ERK mediated DR5 activa-
tion. Reduced DR5 induction was also observed using
siRNA against ERK1/2 as compared to scrambled siRNA
(Fig. 4e).
Thus ERK activation was found to be a key signaling
mechanism upstream DR5 mediated apoptosis by DAT1
in colon cancer cells with both wild type and nonfunc-
tional p53.
Ras/Raf/MEK pathway plays an important role up-
stream of ERK kinase activation. Mutations in the sev-
eral isoforms of the small GTPase Ras or Raf kinase
superfamily of proteins were found to be associated with
different types of human cancers [51, 52]. We thus
wanted to see the effect of Ras/Raf mutation on thesignaling and DAT1 activity in colon cancer cell lines.
The IC50 values of DAT1 and Ras/Raf mutational status
in five different cell lines are shown in Table 2. The
apoptosis induction, as measured by chromosome con-
densation, was also done in the cell lines Colo 320 DM
and Caco2 (Additional file 2: Figure S2) with wild type
Ras/Raf. It was observed that at approximately 1.5 times
the IC50 concentration, DAT1 was able to induce only
38 and 32 % apoptosis respectively in these cells (Fig. 1
for comparison with other cell lines). Further, as shown
in Fig. 5, DAT1 was found to activate ERK in SW 480
and HCT116 cell lines where Ras mutations [53–55]
were noted but it was unable to activate ERK in Colo
320 DM or Caco2 cell lines with wild type Ras or Raf
[54, 56, 57]. Consequently, DR5 was also found to be up-
regulated upon DAT1 treatment in SW480 and HCT116
cells but not in Colo320 DM or Caco2 cells showing that
DAT1 was more effective to induce apoptosis by modu-
lating Ras/Raf/MEK/ERK mediated death receptor path-
way in cells with Ras/Raf mutation.
We further continued to check the efficacy of DAT1
in vivo using colon cancer xenografts and the signaling
and apoptotic mechanisms therein.
Fig. 3 ERK activation and its nuclear translocation by DAT1 a. Cells were treated with DAT1 for the indicated time periods and immunoblotted
with the respective antibodies. Band intensities of P-p38, P-ERK and P-SAPK/JNK were quantified and were normalized with the levels of p38, ERK
and SAPK/JNK respectively. b. Nuclear translocation of ERK was checked in HCT116 cells by immunofluoresence. Cells were treated with DAT1 for
24 h, fixed and probed with P-ERK antibody followed by alexaflour 488. Nuclei were stained with propidium iodide and imaged using a confocal
microscope. c. Nuclear extract was collected from HCT116 cells and immunoblotting was performed using P-ERK antibody. Lamin was used as
the nuclear loading control
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Tumours were grown in Severe Combined immunodefi-
ciency/Non obese diabetic (SCID/NOD) mice by injectingHCT116 or HCT116 p53 −/− cells subcutaneously. As
shown in Fig. 6, DAT1 treatment for 28 days reduced the
mean tumour volume effectively in a concentration
Fig. 4 (See legend on next page.)
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Fig. 4 Apoptosis by DAT1 upon blocking ERK activation a. Cells were treated with DAT1 in the presence or absence of the MEK inhibitor U0126.
Subsequently, they were fixed and stained with DAPI and imaged in a fluorescence microscope. Percentage of apoptosis was calculated and
plotted as given in Fig. 1. *** denotes p ≤ 0.001 and indicates that the difference between the percentage of apoptosis caused by DAT1 in
presence and absence of the inhibitor is extremely significant. b Cells were treated with DAT1 for 24 h with or without the presence of the MEK
inhibitor and cell lysates were collected. Caspase 3 assay was performed according to manufacturer’s instructions and analysed as given in the
methods section. ** for p ≤ 0.01 and indicates significant difference in the fluorescence intensities arising due to caspase 3 activation in the
presence and absence of the inhibitor. c. ERK was inhibited by siRNA against ERK, followed by DAPI staining in the presence or absence of DAT1
and the percentage of apoptosis was calculated and plotted. d,e. Lack of DR5 activation upon blocking ERK activation was checked by western
blotting. Indicated cell lines were treated with DAT1 for a period of 18 h in the presence or absence of the inhibitor (d) or in the presence or
absence of ERK siRNA (e)
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xenograft models.
Acute and Sub- acute toxicity studies of DAT1
To rule out the possibility that the efficacy of DAT1 in
tumours is not due to toxicity of the compound in mice,
we determined both the acute and sub-acute toxicity of
DAT1 in Swiss Albino mice for the range of concentra-
tions used for xenograft studies. In acute toxicity studies,
where single doses were administered to different
groups, there were no signs of weight loss, dehydration,
mortality or behavioural change after 14 days upto
50 mg/kg of DAT1 (Additional file 3: Table S1).
In sub-acute toxicity studies, animals were adminis-
tered with 4, 8 or 16 mg/kg of DAT1 on alternate days
for the first 10 days and twice weekly thereafter for a
period of 3 months and then compared with the control
group of animals. At the end of 3 months, there was no
significant change in the weight. Further, as shown in
Table 3, hematological analysis detected no significant
change in the RBC and WBC content of the treated
mice from the control mice indicating that there was no
hematotoxicity. The serum AST, ALP, BUN and creatin-
ine levels of the treated mice also did not vary much
from the control values indicating that the drug did not
induce hepato and renal toxicity (Table 3). The serum
ALT level remained similar to the control for the groups
that were administered with 4 or 8 mg/kg DAT1. How-
ever, the ALT level increased for mice that were admin-
istered 16 mg/kg of DAT1. But the increase could be
attributed to solvent toxicity as the vehicle controlTable 2 Comparison of IC50 values of DAT1 in Ras/Raf mutated
and wild type cell lines. The respective cell lines were treated
with DAT1 for 48 h at different concentrations followed by MTT
assay. IC50 values were calculated using the programme Origin
Cell lines Ras/Raf mutation status [53, 54, 64] IC50(μM)
SW 480 Ras mutated,Raf wild type 0.795 ± 0.09
HT 29 Raf mutated,Ras wild type 0.2 ± 0.08
HCT116 Ras mutated,Raf wild type 0.3 ± 0.08
Colo 320 DM Wild type Ras and Raf 0.6546 ± 0.048
Caco 2 Wild type Ras and Raf 5.315 ± 0.1622containing similar amount of cremaphor/ethanol showed
similar toxicity for ALT.
Induction of apoptosis in the tumour tissues
We further checked whether the reduction of tumour
sizes were due to apoptosis induction by DAT1. Apoptosis
induction in the tumour tissues was analyzed by tunnel
assay. As seen in (Fig. 7), there were much more staining
in the treated tissues as compared to the control tissues
indicating prominent apoptosis in DAT1 treated colon xe-
nografts with both wild type and nonfunctional p53. This
was also confirmed by immunohistochemistry, where the
tissues were probed with active caspase 3 antibody. Here
also, more cells showed positive staining for active caspase
3 in the treated tissues as compared to the control tissues
(Fig. 7) confirming more apoptosis in the treated tissues.
Activation of DR5 and P-ERK in the tumour tissues
Experiments in colon cancer cell lines have shown that
DAT1 is causing DR5 and P-ERK activation. In order to
confirm these observations in vivo, DR5, P-ERK, P-JNK/
SAPK and P-p38 levels were checked in tissues from
both p53 wild type and knock out mice by immunohis-
tochemistry. Clearly, as indicated by the increase in blue
staining, DR5 and P-ERK levels increased in the treated
tissues as compared to the control tissues showing acti-
vation of the respective proteins by DAT1 (Fig. 8a -b).
However, consistent with the in vitro results, the tissues
labeled with P-p38 and P-JNK/SAPK antibodies dis-
played similar staining pattern in both treated and con-
trol tissues showing that these pathways were not
activated by DAT1 in colon tumours.
DR5 and P-ERK activation was also confirmed by
western blotting. Blots from three different mice are
shown in Fig. 9. The levels of DR5 and P-ERK were
found to be more in the treated tissues as compared to
the control tissues, thus supporting our findings from
cell line studies.
Discussion
The protein p53 is involved in transcription or suppres-
sion of many genes that are involved in apoptosis, autoph-
agy, cellular differentiation and angiogenesis. It protects
Fig. 5 Comparison of ERK activation in cell lines of differential Ras/Raf mutational status. SW480, HCT116, Colo320 DM and Caco 2 cell lines were
treated with DAT1 (~1.5 times IC50 concentrations). ERK or DR5 activation was checked by western blotting after probing with the respective
antibodies. The band intensities were normalized to the levels of actin and P-ERK/ERK ratios were found out
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and it has been found that cancers with nonfunctional p53
are difficult to control and treat. Thus our findings in this
study that the diaminothiazole DAT1 is effective in colon
cancer cells and tumour xenografts even with nonfunc-
tional p53 are important.
DAT1 mediated apoptosis was earlier shown to be trig-
gered by both mitochondria mediated and death receptor
mediated pathways. It was also shown that unlike many
other drugs, the extrinsic or death receptor pathway trig-
gered by DAT1 in colon cancer cells was independent of
the intrinsic pathway and played the major role in inducing
apoptosis [30]. p53 is almost always linked with the intrinsic
pathway whereas there are various reports that show that
the extrinsic pathway can be both p53 dependent or inde-
pendent depending on the nature of the stress and environ-
ment. Since DAT1 was active even in cells where the
intrinsic pathway was blocked, we were interested to study
whether it would be active in cancers with nonfunctional
p53. From in vitro and in vivo studies, we have found that
DAT1 is effective both in cell lines and tumours with wild
type or nonfunctional p53 status. In the in vivo studies, our
results show that the efficiency was about 19 % less (53.4 %
vs. 72.3 % inhibition) in case of tumours bearing HCT116
p53 −/− cells as compared to HCT116 cells for DAT1 treat-
ment of 20 mg/kg (Fig. 6b). The somewhat reduced efficacy
in the later case is possibly due to the involvement of p53
in the less prominent intrinsic pathway of apoptosis in-
duced by DAT1. A confirmation of this hypothesis came
from the fact that DAT1 induced the phosphorylation andnuclear localization of p53 in HCT 116 cells (Additional
file 4: Figure S3).
In this report we have found that DAT1 can trigger
death receptor 5 independent of p53. p53 independent
upregulation of DR5 has been reported earlier in certain
cases. Urasolic acid, a triterpene, was shown to upregu-
late DR4 and DR5 independent of p53 through the
involvement of reactive oxygen species and JNK [35].
Proteasome inhibitors and TRAIL receptor expression
by glucocorticoids and interferon-gamma were also re-
ported to have p53-independent upregulation of DR5
[34, 36]. Upstream activation of ERK but not the other
map kinases was found to be a regulator of DR5 upregu-
lation in DAT1 induced apoptosis in colon cancer as
both inhibition of MEK by the selective inhibitor U0126
and small RNA mediated downregulation of ERK signifi-
cantly reduced DR5 activation and DAT1 mediated apop-
tosis. This is in accordance with earlier reports that link
extra cellular signal regulated kinase pathway and DR5 acti-
vation [48–50]. Paclitaxel (Taxol), another antimitotic drug
that is widely used in clinics, also has been reported to
strongly activate ERK and P-p38 in breast cancer cells and
induce apoptosis in a p53 independent way [40]. Whether
the efficacy of taxol and DAT1 in p53 defective tumours
through ERK and DR5 activation is related to their antimi-
crotubular property, is not known at this point.
Furthermore, DAT1 was found to be more active in
inducing apoptosis in colon cancer cell lines where the
small GTPase protein Ras or its downstream kinase Raf
were mutated. This could be because in these cell lines,
Fig. 6 Effect of DAT1 on colon cancer xenografts. HCT116/HCT116 p53 −/− cells were injected subcutaneously into SCID/NOD mice. Once the
tumour volume reached about 20–80 mm3, DAT1 was administered intraperitoneally. a. Photographs of SCID mice showing decreased tumour
size upon DAT1 treatment. b. Tumour volumes were measured weekly both in control and the treated tissues and were plotted against the
number of days. The statistical significance of differences in tumour volumes upon treatment are denoted as * for p ≤ 0.05, ** for p ≤ 0.01 and ***
for p ≤ 0.001
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to cells where Ras or Raf kinase were of wild type. In
the later cases, the limited apoptosis by DAT1 could beinduced only by the intrinsic pathway and the cell
death might also be contributed by some other death
mechanisms.
Table 3 Analysis of blood parameters upon DAT1 treatment. Swiss Albino mice were injected with DAT1 as given in the methods
section. After 3 months, serum ALP, ALT, AST, BUN and creatinine levels were determined according to manufacturer’s protocol.
WBC and RBC count was taken using hemocytometer. Group I: Control, Group II: 4 mg/kg, Group III: 8 mg/kg, Group IV: 16 mg/kg
and Group V: vehicle control
Groups ALT (U/L) ALP (U/L) BUN (mg/dL) AST (U/L) Creatinine (mg/dL) RBC (million/mm3) WBC (per mm3)
Group I 46.45 ± 8.1 193.64 ± 10.1 24.16 ± 5.28 123.84 ± 26.14 0.743 ± 0.06 4.9 ± 0.52 7500 ± 1742
Group II 54.38 ± 4.15 158.32 ± 8.32 29.8 ± 1.25 128 ± 25.1 0.82 ± 0.1 4.42 ± 0.75 8100 ± 1979
Group III 53.845 ± 4.81 136.48 ± 10.69 29.8 ± 1.26 128.165 ± 1.87 0.76 ± 0.07 4.48 ± 0.34 6220 ± 1626.34
Group IV 148.39 ± 14.55 155.61 ± 15.15 29.8 ± 1.27 162.67 ± 12.73 0.58 ± 0.09 4.475 ± 0.26 4550 ± 264.575
Group V 140.64 ± 8.59 198.51 ± 10.1 29.8 ± 1.28 167.67 ± 10.73 0.658 ± 0.042 5.08 ± 0.438 7267 ± 141.42
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pathway in cancers and activation of this pathway is shown
to play role in both cell proliferation and apoptosis [58, 59].
Mutations in Ras or Raf are known to induce constitutive
activation of ERK which further act as a transcription factor
to many prosurvival or pro apoptotic proteins. In our exper-
iments, however, we did not get more constitutive activity
of ERK in HCT116, HT29 (data not shown) or SW480 cells
with mutated Ras or Raf as compared to Colo320DM or
Caco2 cells where these proteins were reported to be of wild
type (Fig. 5). There is however a report that higher expres-
sion of the mitogen-activated protein kinase phosphatase-1
(MKP1) may inactivate ERK in HCT116 cells as opposed to
Caco2 cells where MKP1 expression is low giving rise to
sustained ERK activation [60]. About 33 % of cancers have
mutations in Ras and about 8 % harbor mutations in Raf.
Considering the high importance of this pathway in differ-
ent types of cancer, inhibitors are now in clinical trials [61,
62] . However, these inhibitors target the prosurvival role of
this pathway activation. Considering this, role of DAT1 to
induce the proapoptotic function of this pathway would be
of high interest and it provokes our quest to know the fine
tuning of this pathway for the initiation of survival response
or apoptotic response.
Conclusions
Thus, the diaminothiazole DAT1 is able to induce apop-
tosis in both in vitro and in vivo colon cancer models
overcoming the lack of p53 functionality through ERK
mediated upregulation of Death Receptor 5. Further,
DAT1 is more effective to induce apoptosis in cell lines
with mutated Ras oncoprotein or its downstream kinase
Raf. These findings, along with its minimal toxicity in
both acute and sub-acute studies, place diaminothiazoles
as highly beneficial candidates for cancer chemotherapy
and call for the need of clinical trials.
Methods
Materials
Cell lines HCT116 and SW480 were from ATCC. SW620
and HT29 were from NCI. HCT116 p53 −/− was a kind
gift from Dr. Bert Vogelstein. Caco2 and Colo 320 DM celllines were procured from the national repository of
National Centre for Cell Sciences, Pune, India. DAT1 was
synthesized by slight modification of the method described
earlier [63]. Vinblastine, taxol, 5-Fluoro uracil, DAPI, propi-
dium iodide and U0126 were from Sigma, USA. siRNA
construct for ERK1/2 was obtained from Santacruz
Biotechnology. DMEM and PSN antibiotic mixture were
purchased from Invitrogen, USA. MTT and Caspase 3
fluorogenic substrate were from USB and BD pharmingen,
respectively. Tunnel assay kit was from R & D Biosystems,
USA and immunohistochemical kit was purchased from
Vector Labs, USA. Kits for detection of ALP, AST, ALT,
Creatinine and BUN levels in serum were from Aspen
Laboratories, India.
Antibodies
DR5 antibody was from Imgenex, Canada or Abcam,
UK, DR4 antibodies were procured from Imgenex,
Canada. Antibody against Fas was from Sigma and anti-
bodies against P-ERK, P-p38, P-JNK/SAPK, Caspase 3
and 8 were from Cell Signaling Technologies, USA or
Abcam, UK. Lamin, β actin, ERK, p38 and JNK, SAPK
antibodies were purchased from Santacruz Biotechnol-
ogy, USA. Alexafluor 488, 568 and 633 antibodies were
from Molecular Probes (Invitrogen). Anti rat tubulin
marker antibody was from Abcam, UK.
Maintenance of cell lines
The cell lines used in the study were maintained in
DMEM or RPM1 containing 10 % FBS with 1X Penicillin
Streptomycin Neomycin antibiotic mixture. The cells were
incubated at 37 °C in a CO2 incubator in humid condition
containing 5 % CO2. From the reference stock, frozen
stocks of cells were made within passage 3 and stored in
liquid nitrogen. For experiments, cells were used within
3 months after revival.
DAPI staining for detection of apoptosis
The cells were grown on coverslips in 24 well plates and in-
cubated with respective drug or inhibitor for 24 h. They
were then washed with PBS, fixed with chilled methanol-
EDTA for 10 min and rehydrated with PBS for 10 min at
Fig. 7 Measurement of apoptosis in tumour tissues. A. Tumours bearing HCT116 or HCT116 p53 −/− cells were excised after 28 days of injection,
fixed in 4 % paraformaldehyde and preserved in 30 % sucrose and cryosectioning was performed. a,c. Tunnel assay. Brown color (DAB staining)
indicates the apoptotic cells. b,d. Immunuhistochemical staining of active caspase 3 in HCT116 and HCT116 p53 −/− . Alkaline phophatase detection
method was used to visualize the antibody bound cells. B. The area showing blue/brown colour were quantified by Image J software and plotted.
p values for the differences among treatment values and control values were obtained by unpaired t test,** stands for p ≤ 0.001 and * for p ≤ 0.01.
At least five fields were analysed
Thamkachy et al. Molecular Cancer  (2016) 15:22 Page 12 of 17room temperature. Successively, the cells were treated with
DAPI (0.5 μg/ml) for 2 min in the dark. The coverslips
were then mounted on fluoromount G and viewed at 40X
in the UV region using a fluorescence microscope (Olym-
pus IX71).
Western blotting
Cells were grown to 70–80 % confluency in 60 mm culture
dishes. After drug treatment, they were harvested and lysed.Protein samples from tissues were collected by homogeniz-
ing the tissue in the presence of lysis buffer, followed by cen-
trifugation for 20 min. The protein samples were run in a
10–12 % gel and transferred on to a PVDF membrane. The
membranes were probed with specific primary antibodies
(1:1000) overnight followed by secondary antibodies conju-
gated with horse radish peroxidase/alkaline phosphatase
(1:2000) for 1 hr at room temperature and were developed
by chemiluminescence or alkaline phosphatase method.
Fig. 8 Signaling pathway elucidated by DAT1 in tumour tissues. a-b. Sections were made from control and DAT1 treated tumour tissues and
immunohistochemistry was performed using the respective antibodies as described in Fig. 7. c The positively stained area were quantified using
Image J and were plotted to show activation of the respective proteins followed by determination of statistical significance using unpaired t test
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Fig. 9 ERK and DR5 activation in the tumour tissues detected by immunoblotting. Western blots showing activation of DR5 and pERK in the
treated tissues. Tissue lysates were analyzed by SDS-PAGE and western blotting was performed with the respective antibodies as shown. Blots
were developed by chemiluminescence
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Cells were seeded in 96 well plates. At about70 % con-
fluency, they were treated with different concentra-
tions of drugs either individually or in combination.
After 48 h, MTT assay was done (Mossmann 1983)
and absorbance was measured at 570 nm (Biorad
Microplate reader). Percentage viability was plotted
against the respective concentrations of the drugs and
half inhibitory concentration (IC50) was calculated
with the non linear regression programme of Origin.
Immunofluorescence
Cells were seeded on coverslips in 35 mm dishes and
were treated with DAT1 for the indicated time period.
After fixing with methanol-EDTA and blocking, they
were probed with the primary antibodies overnight
followed by alexafluor 488. Nuclei were stained withpropidium iodide and were imaged in a confocal
microscope (Leica SP2) or in Olympus IX71.
Caspase 3 fluorometric assay
The enzymatic activities of caspase 3 was assayed spec-
trofluorimetrically using fluorogenic substrates from BD
Pharmingen according to manufacturer’s instructions
and then quantitated using a fluorescence plate reader
(Tecan Infinite M200) with the excitation and emission
wavelengths of 400 and 505 nm, respectively. The values
of relative fluorescence units with respect to the controls
were plotted against different treatments.
Extraction of nuclear and cytoplasmic fractions
105 cells were treated with DAT1 for the indicated time
period after attachment. Following incubation, 0.5 mL
Buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
Thamkachy et al. Molecular Cancer  (2016) 15:22 Page 15 of 17EDTA, protease inhibitors) was added, and cells were
collected by scraping. After centrifugation at 13000 rpm for
3 min, the supernatant was preserved as cytoplasmic
extract. To the pellet 150 μL of Buffer B (20 mM HEPES,
pH 7.9, 0.4 M NaCl,1 mM EDTA, 10 % Glycerol) was
added and kept in ice for 1 h with intermittent shaking
followed by centrifugation at high speed. The supernatant
was collected as the nuclear extract.siRNA transfection
Cells were seeded in 35 mm dishes and after attachment,
they were transfected with ERK or control siRNA using
the transfection reagent lipofectamine 2000. The cells
were further incubated for 72 h before addition of drug
and processing for western blotting or DAPI staining.Animal experiments
Swiss Albino mice and SCID/NOD mice were used for
the experiments. Animals weighing 25–30 g and age of
9–11 weeks were used in the experiments. All the
animal experiments were conducted as per the approved
guidelines of Institute Animal Ethics Committee which
is under the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA),
Govt. of India. The mice were handled and housed in
conventional plastic cages and maintained on an auto-
matic 12 h lighting cycle at a temperature of 22-24 °C.Acute toxicity studies
In acute toxicity studies, Swiss Albino mice were divided in
to six groups of six animal each and DAT1 (12–50 mg/kg)
was administered intraperitoneally (i.p) and observed for
14 days for signs of weight loss, dehydration or mortality.
DAT1 was dissolved in vehicle cremaphor:ethanol (1:1) and
diluted in 0.9 % saline.Sub-acute toxicity studies
In sub-acute toxicity studies, Swiss albino mice were
divided into five groups of eight animals each. Three
groups of Swiss Albino mice were administered (i.p in-
jection) with 4, 8 or 16 mg/kg DAT1, and the control
and vehicle control groups were administered with 0.9 %
saline or vehicle respectively. Injections were given every
alternate day for the first 10 days and after that, twice
weekly for a period of 3 months. After 3 months animals
were sacrificed and whole blood, liver and kidney were
collected. Hematotoxicity was checked by RBC and
WBC count. Hepatotoxicity was measured by monitor-
ing the serum ALT and AST levels. Nephrotoxicity was
measured by monitoring BUN and creatinine levels in
the serum. ALP activity was measured for detection of
liver or bone toxicity.Xenograft studies
SCID/NOD mice were divided into groups of ten and
allowed to acclimatize. After 5 days, tumours were
raised by injecting HCT116 or HCT116 p53 −/− cells
(1.5 × 105 cells suspended in PBS) subcutaneously in
the inner flank region. Once the tumour volumes reached
20–80 mm3, drug was administered intraperitoneally, thrice
a week at different concentrations.
Immunohistochemistry
Tumour tissues from the treated and control mice were
collected after sacrificing the mice and fixed in 4 % para-
formaldehyde and kept at 4 °C for 12 h. Tissues were
then stored in 30 % sucrose until cryo-sectioning.
Tissues were sectioned in a Leica CM1850uv cryostat
and then processed for immunohistochemistry according
to the manufacturer’s protocol (Vector Labs) using the
appropriate antibodies. The antibody bound area was
visualized using alkaline phosphatase detection method.
Tunnel assay
Fixed tissues were stored in sucrose and sectioned in a
cryostat. The sections were collected in gelatin coated
slides and tunnel assay was done according to manufac-
turer’s protocol (R & D Biosystems, USA). Diaminobenzi-
dine (DAB) staining was used to detect the apoptotic cells.
Analysis of data
The number of apoptotic cells was determined by count-
ing from at least five fields. Results are shown as mean ±
standard deviation. Standard deviations were determined
from three independent experiments. Biorad quantity one
software was used for densitometric analysis of blots. Blots
were normalized with actin, ERK, p38 or JNK/SAPK
wherever necessary. For animal experiments, results are
shown as mean ± standard error of mean. Data for at
least six animals for sub-acute toxicity studies and eight
animals for xenograft studies were analyzed. Unpaired
student’s t test was used for finding the statistical
significance and p ≤ 0.05 were considered as statistically
significant.
Additional files
Additional file 1: Figure S1. Comparison of apoptosis in HCT116 and
HCT116 p53 −/− cells treated with vinblastine : Cells were treated with
vinblastine (0.01 μM) for 24 h and DAPI staining was done and chromatin
condensation was visualized by fluorescence microscopy. (TIF 565 kb)
Additional file 2: Figure S2. Induction of apoptosis by DAT1 in colon
cancer cell lines with wild type Ras and Raf. Left. Indicated cell lines were
treated with 1.5 times IC50 concentration of DAT1 for a period of 24 h
and stained with DAPI. Right. Apoptosis was quantitated by counting the
number of cells with condensed chromosomes and percentage was
calculated as compared to the total number of cells. Cells were counted
from five different fields. Values expressed in the graph are the average
values from two independent experiments. (TIF 902 kb)
Thamkachy et al. Molecular Cancer  (2016) 15:22 Page 16 of 17Additional file 3: Table S1. Acute toxicity studies of DAT1. Swiss
Albino mice were divided into 6 groups of 6 mice each and were
injected with either DAT1 or vehicle intraperitoneally. The mice were
observed for a period of 14 days and the weights were taken before
drug administration and after 14 days. Group I: 12 mg/kg, Group II:
20 mg/kg, Group III: 30 mg/kg, Group IV: 40 mg/kg, Group V: 50 mg/kg.
(DOC 30 kb)
Additional file 4: Figure S3. p53 activation in HCT116 cells. a. p53
activation was checked in HCT116 cells by western blot with phosho p53
antibody (Ser 15). b. Nuclear translocation of p53 was checked by
immunofluorescence using an antibody against p53 and was visualized
by Alexa 488. Nuclei were stained with propidium iodide. c. Nuclear
localization was checked by western blotting against p53 antibody. An
antibody against Lamin was used as a nuclear marker. (TIF 1599 kb)
Abbreviations
ALP: alkaline phosphatase; ALT: alanine amino tranferase; AST: aspartate
amino tranferase; BUN: blood urea nitrogen; DAPI: 4’,6-diamidino-2-
phenylindole; DAT1: 4-Amino-5-benzoyl-2-(4-methoxyphenylamino) thiazole;
DR4: death receptor 4; DR5: death receptor 5; ERK: extra cellular signal
regulated stress kinase; JNK: c-Jun N-terminal kinase/stress activated protein
kinases; MEK: mitogen/extracellular signal-regulated kinase.
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